ARGX

argenx SEC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1,020.00

Analysis reference price unavailable

Analysis 2026-10-09 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$840.00

Analysis reference price unavailable

Analysis 2026-10-09 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$620.00

Analysis reference price unavailable

Analysis 2026-10-09 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-09

AI commentary

The October 8 close was down 11.83%, consistent with the market prioritizing UNITY futility over same-day positive FB102 data. News tone is negative despite continued commercial growth. The social, options, short-interest, and employee figures are unavailable in the packet; zero entries above mean unavailable, not neutral measurements. Verified post-event analyst target revisions were also unavailable. October 8 close [#PR-2026-10-08-UNITY] UNITY release [#PR-2026-10-08-FB102] FB102 release

RankAlpha Sentiment Codex - 2026-10-09

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-22catalystOctober 22 commercial update tests VYVGART growthMedium impact

argenx scheduled third-quarter results for October 22. The decision-relevant measure is whether VYVGART sales sustain momentum after second-quarter product sales reached $1.5 billion, up 60% year over year. This is a commercial-uptake test, not an assumed earnings beat. [#PR-2026-07-23] Company results

2026-12-31eventEMPASSION MMN readout tests a second pipeline assetHigh impact

argenx expects fourth-quarter 2026 topline results from the registrational EMPASSION study of empasiprubart in multifocal motor neuropathy. A positive result could diversify the pipeline beyond efgartigimod; failure would compound the October UNITY setback. [#PR-2026-07-23] Company results

2027-06-30catalystFB102 Phase 3 development plan after celiac Phase 2 successHigh impact

FB102 met its Phase 2 celiac primary endpoint during a gluten challenge (p=0.0176), and argenx plans Phase 3 development. Trial design and timing have not been announced; the date here is a monitoring estimate, not company guidance. Phase 2 results do not establish Phase 3 success. [#PR-2026-10-08-FB102] Company release

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-09 • Updated nightlySource: Internal modelMethodology